The RCP has jointly produced recommendations on cannabis-based products for medicinal use (CBPM) with the Royal College of Radiologists (RCR) and in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists.
There is good evidence that cannabinoids are effective in preventing chemotherapy-induced nausea and vomiting (CINV) but they have a high side effect profile and there are more efficacious agents available. Cannabinoids should remain an option for those who have failed standard therapies but not used as a first-line treatment. There is limited research available from which to create guidance on the effect of CBPM on pain in palliative care patients, including those with cancer. Studies show mixed results or statistically significant results of uncertain clinical significance.